Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 36,800 shares, an increase of 1,500.0% from the December 31st total of 2,300 shares. Based on an average trading volume of 214,500 shares, the short-interest ratio is presently 0.2 days.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS CHGCY traded down $0.17 during midday trading on Tuesday, reaching $20.76. 251,326 shares of the stock were exchanged, compared to its average volume of 189,677. The company has a 50 day simple moving average of $21.62 and a 200 day simple moving average of $22.44. The stock has a market capitalization of $68.32 billion, a P/E ratio of 26.62 and a beta of 0.81. Chugai Pharmaceutical has a twelve month low of $14.52 and a twelve month high of $26.00.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Friday, October 25th. The company reported $0.22 EPS for the quarter. The business had revenue of $2.12 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.85% and a return on equity of 22.30%. On average, research analysts expect that Chugai Pharmaceutical will post 0.78 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.